EMAIL THIS PAGE TO A FRIEND

Journal of diabetes research

Combination therapy with oleanolic acid and metformin as a synergistic treatment for diabetes.


PMID 25789330

Abstract

Type 2 diabetes is a chronic disease that cannot be treated adequately using the known monotherapies, especially when the disease progresses to an advanced stage. In this study, we explore the possibility of treating the disease with a novel combination approach of oleanolic acid (OA), a glycogen phosphorylase (GP) inhibitor, and metformin. Db/db mice were randomly divided into four groups: a db/db control group, db/db mice treated with OA (250 mg/kg), db/db mice treated with metformin (100 mg/kg), and db/db mice treated with a combination of OA and metformin. All mice were treated for four weeks. The effects of the treatments on glucose homeostasis were measured using an OGTT, an assessment of insulin sensitivity and signaling in the liver, and the hepatic glucose production. Combination therapy with OA and metformin significantly reduced the blood glucose and insulin levels and improved the liver pathology compared with that for the monotherapy in the db/db diabetic mouse model. We also found that the combination therapy significantly increased the mRNA expression of glycogen synthesis and decreased the GP, PGC-1α, PEPCK1, and G-6-Pase levels. In addition, the combination therapy with OA and metformin significantly increased the phosphorylation of AKT, PI3K, AMPK, and ACC and decreased the protein expression levels of G-6-Pase, PEPCK1, and TORC compared with those for either monotherapy. The combination therapy also reduced the phosphorylation of mTOR and CREB. Our results suggest that the combination therapy with OA and metformin has synergistic effects on the symptoms of db/db diabetic mice by improving glucose and insulin homeostasis.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

32883
4-tert-Octylphenol monoethoxylate solution, 1 μg/mL in acetone, analytical standard
C16H26O2
32882
4-tert-Octylphenol monoethoxylate solution, 10 μg/mL in acetone, analytical standard
C16H26O2
C2155000
Cholesterol, European Pharmacopoeia (EP) Reference Standard
C27H46O
PHR1533
Cholesterol, Pharmaceutical Secondary Standard; Certified Reference Material
C27H46O
47127-U
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
C27H46O
E0396
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, BioXtra, ≥97 .0%
C14H24N2O10
E3889
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, for molecular biology, ≥97.0%
C14H24N2O10
E4378
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, ≥97.0%
C14H24N2O10
03777
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid, BioUltra, for molecular biology, ≥99.0% (T)
C14H24N2O10
03609
Ethylenediaminetetraacetic acid, BioUltra, ≥99.0% (KT)
C10H16N2O8
03620
Ethylenediaminetetraacetic acid, ≥98.0% (KT)
C10H16N2O8
03690
Ethylenediaminetetraacetic acid solution, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
C10H16N2O8
47072
Fluoride ion solution for ISE, 0.1 M F-, analytical standard (for ion-selective electrodes)
FNa
80373
Fluoride, certified anion standard solution, 1000 mg/kg F-, for ion chromatography, certified by BAM, according to ISO 17025
FNa
71383
Sodium chloride, tested according to Ph.Eur.
ClNa
71387
Sodium chloride, certified reference material for titrimetry, certified by BAM, according to ISO 17025, ≥99.5%
ClNa
PHR1321
Sodium chloride, Pharmaceutical Secondary Standard; Certified Reference Material
ClNa
S7920
Sodium fluoride, BioXtra, ≥99%
FNa
S6776
Sodium fluoride, BioReagent, suitable for insect cell culture, ≥99%
FNa
450022
Sodium fluoride, anhydrous, powder, 99.99% trace metals basis
FNa
215309
Sodium fluoride, 99.99% trace metals basis
FNa
PHR1408
Sodium Fluoride, certified reference material
FNa
67414
Sodium fluoride 0.5 M solution
FNa
919
Sodium fluoride solution
FNa